The Promise of Stem Cells

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

At the plenary session at the AAPS Annual Meeting, two researchers presented studies targeting completely different areas of stem cell research, but their work focused on the same ultimate goal: finding new therapies.

At the plenary session at the AAPS Annual Meeting, two researchers presented studies targeting completely different areas of stem cell research, but their work focused on the same ultimate goal: finding new therapies.

Margaret A. Goodell, PhD, of Baylor College of Medicine, presented her work on adult hematopoietic stem cells (the stem cells in bone marrow that regenerate blood), emphasizing gaining an understanding of what happens to stem cells as they age. Her results showed a 10% difference in gene activity between young and old stem cells, and many of these differences mirror gene activity already linked to aging. A key example was a 44-fold increase in Cox-2 activity in older cells, associated with inflammation, one example of a general increase in cell activity linked to immune responses. Of the cell activities seen to decrease, many were linked to a decline in the amount of chromatin activity, which could drive additional changes in the body associated with age, Goodell said.

Douglas W. Lasordo, MD, of Tufts University, presented preliminary results of a pilot clinical trial studying autologous stem cells for untreatable coronary disease. In the double-blind, placebo-controlled study of 24 patients, CD 34+ cells were injected into ischemic regions of the heart. Initial results are hopeful, Lasordo said, because treated patients showed increased tolerance for exercise and reduced angina after six months of treatment, and no serious adverse events were reported.

When asked how autologous stem cells compared to stem cells from other humans or from animals, Lasordo said studies have shown that the patients' own cells were somewhat less effective. "You can look at this as a glass half empty or a glass half full," he said. "It's too bad that the patients' own cells are not as good, but that information also offers potential for finding diagnostic and therapeutic targets. This clinical research may lead back to the lab."

Participants in the symposium were:

Hematopoietic Stem Cells: Biology and Potential Therapeutic Applications
Margaret A. Goodell, PhD
Baylor College of Medicine

Adult Autologous Stem Cells for Untreatable Coronary Disease: A Pilot Clinical Trial
Douglas W. Losordo
MD, Tufts University

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content